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Translational research is essential to develop strategies for the treatment of pulmonary arterial 
hypertension (PAH) using animal models which reproduce the severity, the progressive nature and 
resistance to treatment of human PAH, including severe arterial remodeling and progressive right 
ventricular (RV) failure (1). 
We read with interest the letter by Kojonazariov et al. who propose to have found “severe 
emphysema in the SU5416/Hypoxia (SuHx) rat model of pulmonary hypertension”(2). The authors 
report that Wistar-Kyoto rats exposed to the combination of VEGFR2 inhibition by SU5416 and 
chronic hypoxia had moderately increased RVSP and RV mass compared to normoxic untreated 
animals(2). They applied in vivo micro-computed tomography (CT) to demonstrate an increase in 
lung volume and decreased lung density, an unaltered amount of lung tissue, but an increased air-
to-tissue ratio, and claim these findings were confirmed by histological analysis, including mean 
linear intercept as surrogate of emphysema(2). Indeed, SU5416 has been previously shown to 
induce emphysema in normoxia(3), but this required repetitive SU5416 dosing (3 times weekly 
over 3 weeks) and occurred more predominantly in rats younger than 4 weeks of age (Norbert 
Voelkel, personal communication). In addition, emphysema could be negated, at the cost of the 
development of severe angioproliferative hypertension, by concomitant exposure to hypoxia(4). 
The SuHx model, combining a one-time subcutaneous injection of Sugen (SU5416), that 
blocks VEGF receptor 2 but also other tyrosine kinases, followed by 2-4 weeks of hypoxia(5, 6)(7), 
is the most accepted rodent model for pulmonary arterial hypertension (PAH). Although several 
modifications of the SuHx model exist, the most commonly used study design is the one-time 
injection of 20mg/kg SU5416 s.c. in 6-8 week old Sprague Dawley rats /body weight (180-200g), 
followed by 3 weeks hypoxia (10% oxygen), and subsequently a 1-10 week period in room air, until 
heart-lung function and morphology is assessed. 
Experiments in male Sprague Dawley rats demonstrated that RV systolic pressure (RVSP) 
increases over 90 mmHg in response to SuHx at three(5, 6) or four weeks hypoxia(7), then 
decreases somewhat in some studies but remains elevated at 73 mmHg(7), 91 mmHg(6) and 96 
mmHg upon return to normoxia for additional four(7), six or ten weeks(5, 6), respectively (Table). 
Importantly, at six(6) and ten weeks(5) after the end of hypoxia, plexiform lesions that are very 
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similar to such lesions in humans (IPAH), were frequently found in SuHx rats(5, 6), in addition to 
concentric medial hypertrophy of small- and medium-sized pulmonary arteries(6). Legchenko et al. 
demonstrated that RV failure develops between 1 and 6 weeks after the end of 3 weeks hypoxia in 
SuHx rats, together with progression of pulmonary vascular disease (PVD), loss of peripheral 
pulmonary arterioles, and a metabolic switch in the RV(6). 
The advantages of the SuHx rat versus most other rat PAH models such as monocrotaline 
(MCT) were highlighted by a group of experts and include the intensification of vascular 
remodeling process, leading to the appearance of human-like plexiform lesions, and the virtual 
unresponsiveness to current PAH treatments, correlating well with the common unresponsiveness 
of PAH to therapy in humans(1). 
Importantly, “severe emphysema” has not been previously observed in the SuHx rat model 
of PAH. Based on the report by Kojonazariov et al.(2), we have conducted not only a literature 
search but also analyzed lung histology from different SuHx rat studies in established laboratories 
(Table, Figure). In contrast to Kojonazariov et al., we did not find any severe or even moderate 
emphysema in any of the SuHx models analyzed. (Figure 1; Table). Mean linear intercept (MLI) 
as a surrogate for alveolar enlargement was not significantly different in SuHx vs. untreated control 
lungs (ConNx) from Sprague Dawley rats obtained from Charles River, Sulzfeld, Gemany (Figure 
1A, 1B). The Stewart group measured MLI in Sprague Dawley rats obtained from Harlan, 
Indianapolis, USA, and found a mild (18%) increase in MLI in SuHx vs. naïve no-vehicle control 
(ConNx) rats (8). (Table, Figure 1C, 1D).
Several reasons may explain the differences in the above findings and the recent report by 
Kojonazariov et al.(2): This group studied Wistar Kyoto (2) rather than Sprague Dawley rats that 
have been used by most other groups, and observed a much weaker PAH hemodynamic 
phenotype (RVSP 55mmHg, at 3+2 weeks SuHx) when compared with many other publications 
(i.e., RVSP 91-107mmHg upon return to normoxia for 4-10 weeks; Table)(5-8). It is possible that 
the Wistar rat strain may be more prone to emphysema after SuHx, however, Dean et al. did not 
report any emphysema-like lung phenotype in female Wistar rats exposed to SuHx (RVSP 55 
mmHg)(9). The Stewart group compared the response to SuHx in several different strains of rats: 
While Fischer and Sprague Dawley rats developed similar increases in RVSP to ~100 mmHg(8), 
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Lewis rats exhibited no significant increase in RV pressure, highlighting the importance of 
background in determining the phenotype in the SuHx model. 
In addition to the above strain differences, technical factors may also contribute to the 
differences observed between research groups. While we congratulate Kojonazariov et al.(2) on 
performing in vivo micro-CT to quantify the air-to-lung-tissue volume ratio as a surrogate of air 
space disease (emphysema), it remains unclear whether, and - if so - how the images were gated 
to the respiratory cycle. From the clinical experience, expiratory chest CT lung images must be 
interpreted with caution, and of course yield lower such ratio numbers than end-inspiratory CT 
images. As well, valid measurement of MLI in ex vivo histological studies critically depends on 
standardized tracheal inflation pressure and volume, in the absence of a pleural leackage.
In summary, based on a literature search and the analysis of our own SuHx rat studies 
(Table 1; Figure 1), we cannot confirm the presence of moderate or severe emphysema in the 
established Sugen-hypoxia rat model of PAH. At the most, there may be mild enlargement of 
intraalveolar spaces depending on rat strain, number of SU5146 doses and timing of lung harvest. 
In contrast, there is ample evidence that repetitive SU5416 injections alone (i.e. blockade of 
VEGFR2 and other kinases) in the absence of hypoxia, can produce an emphysema-like lung 
phenotype, but the latter mainly occurs in younger rats where postnatal lung development may still 
be ongoing(3). Our data provide evidence that the Sugen-hypoxia (SuHx) rat model, when yielding 
RVSP consistently > 60 mmHg, using adequate controls and standardized lung inflation, is 
currently one of the best rodent models to study PAH and PVD, including mechanisms of vessel 
loss and RV failure, and as such lacks a biologically relevant emphysema-like lung phenotype.
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Figure 1. Emphysema is – at the most – only a mild phenotype in the SuHx rat model of 
pulmonary arterial hypertension (PAH). 
(A) Representative pictures of Elastica van Gieson staining of the lungs from control normoxia 
(ConNx) and Sugen hypoxia (SuHx) rats. Scale bar: 200 μm. (B) Quantification of mean linear 
intercept (MLI) shows that there is no significant difference between ConNx group and SuHx 
group. (C) Representative pictures of H&E staining of the lungs from ConNx and SuHx rats from 
the Stewart group. Scale bar: 200 μm. (D) Quantification of MLI shows that MLI has a significant 
but mild increase in SuHx compared to ConNx rats. The MLI (also called air space chord length, 
Lm), as a surrogate of air space diameter, was determined as follows:
A/B: The left lung was tracheally filled by 1:1 mix of saline and cryofixative (Tissue-Tek OCT), and 
snap frozen in liquid nitrogen. Lung cryosections (5 μm) were stained with Elastica van Giesson for 
morphometric analysis. Six to eight random fields (100x magnification) for each rat were analyzed 
for mean linear intercept. Five to ten lines of 800 um length were drawn per image, alveolar 
intercepts per line were counted and mean linear intercept was calculated.
C/D: The left lobe of the lung was inflat d via the trachea with 1:1 OCT/saline solution (Tissue-Tek 
OCT) and then removed. The left lobe was then cut into thick cross sections and fixed in 4% 
paraformaldehyde (PFA) for 24 h, rinsed and washed in PBS for 8 hr and stored in 70% ethanol 
until the day of paraffin embedding. Eight random high power fields (100 x magnification) for each 
rat were analyzed for mean linear intercept. Three lines of 1000um length were drawn per image, 
alveolar intercepts per line were counted and mean linear intercept was calculated.
SuHx group: rats injected once with SU5416 20-25 mg/kg/dose s.c., and subsequently exposed to 
chronic hypoxia, i.e. 10% oxygen. A/B: 4 weeks hypoxia, followed by 6 weeks in room air and lung 
harvest. C/D: 3 weeks hypoxia followed by lung harvest). Rat supplier for A/B: Charles River, 
Sulzenfeld, Germany. Rat supplier for C/D: Harlan, Indianapolis, Indiana, USA. For additional 
experimental details, see Table. Columns and error bars represent mean±SEM, n=5-6 per group. 
Non-parametric Mann-Whitney test. ** p < 0.01; n.s., not significant. Scale bar = 200m
TABLE with legend
Table, see subsequent page





Gender, age, weight 
at Su5416 injection
Su5416 brand, single 
dose s.c. (solvent)











Not reported Brand not reported,
20mg/kg (solvent ?)
3+2 ~55 ± 6 Yes,
“severe”
SuHx vs. ConNx comparison:
MLI (histology): ~45 vs 35m,
Air-to-lung tissue volume ratio (CT): 
~2.4 vs. 1.6; p < 0.001










Sci Transl Med, 2018 (6)
Sprague 
Dawley1




3+1, 3+3, 3+6 91 ± 7 No Plexiform lesions at 3+6 weeks very 
similar to human plexiform lesions.
RV failure occurs between 3+1 and 
3+6 weeks (MRI, closed-chest right 
and left heart catheterization).
Dabral et al. 
















4+6 72 ± 2 No SuHx vs. ConNx comparison:
MLI (histology) 47 vs. 46m, n.s.; 









3+4 105 ± 10 Yes, 
“mild”
SuHx vs. ConNx comparison:
MLI (histology) 55 vs. 46m, 
p < 0.01; see Figure 1C, 1D 








3+5 104 ± 13 No Assessed vascular remodeling.
De Raaf et al.







4+3 73 ± 2 No RSVP monitoring by telemetry. 







20mg/kg (solvent ?) 
3+2, 3+5, 3+10.5 96 ± 11 No Plexiform lesions at 3+10.5 weeks 
indistinguishable from human plexiform 
lesions. 
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Table. Sugen-hypoxia rat models of pulmonary arterial hypertension (2010-2019). The rat model consists of a one-time subcutaneous injection of 
Su5416 (Sugen), followed by a period of 3-5 weeks of hypoxia (10% oxygen). Subsequently, the rats were returned to room air (normoxia) for 0 to 11 weeks 
(for example, 3 + 6 weeks means 3 weeks hypoxia followed by 6 weeks normoxia. The reported RVSP and quantitative tissue analysis was obtained at the 
last time point, labeled in bold in the 5th column. In Kojonazarov et al., Wistar Kyoto rats were obtained from the vendor Janvier Labs, Germany. 1In these 
studies, male Sprague-Dawley rats were obtained from the vendor Charles River, Sulzfeld, Germany. 2In these studies, male Sprague-Dawley rats were 
obtained from the vendor Harlan Laboratories, Indianapolis, Indiana, USA. Abbreviations: CMC, carboxymethylcellulose; ConNx, naïve (no vehicle) normoxic 
control; CT, computed tomography of the chest; MLI, mean linear intercept, a surrogate parameter for intraalveolar space and emphysema; MCT, 
monocrotaline; n.s., not significat; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PASP, pulmonary arterial systolic pressure; RV, right ventricle; 
LV, left ventricle; RVSP, right ventricular systolic pressure; RVH, right ventricular hypertrophy; SuHx, Sugen Hypoxia.
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